Loading company…
Noxxon Pharma develops therapies for aggressive cancers by targeting the tumor microenvironment.
Noxxon Pharma develops cancer therapies that target the tumor microenvironment. Its lead product, NOX-A12, is being studied for aggressive cancers including glioblastoma and pancreatic cancer. Founded in 1998, the company is based in Berlin, Germany. In September 2016, it raised EUR 17.000 mn in a PIPE from Atlas Special Opportunities LLC.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in